compro: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Padagis Us	COMPRO	prochlorperazine	SUPPOSITORY;RECTAL	040246	ANDA	Padagis US LLC	0574-7226-12	12 PACKET in 1 CARTON (0574-7226-12) / 1 SUPPOSITORY in 1 PACKET	2000-09-01
Padagis Us	COMPRO	prochlorperazine	SUPPOSITORY;RECTAL	040246	ANDA	PD-Rx Pharmaceuticals, Inc.	55289-119-02	2 SUPPOSITORY in 1 BOTTLE, PLASTIC (55289-119-02)	2000-09-01
Padagis Us	COMPRO	prochlorperazine	SUPPOSITORY;RECTAL	040246	ANDA	PD-Rx Pharmaceuticals, Inc.	55289-119-06	6 SUPPOSITORY in 1 BOTTLE, PLASTIC (55289-119-06)	2000-09-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The pharmaceutical landscape is complex, with a multitude of suppliers spanning manufacturing, distribution, and raw material sourcing. Compro, a pharmaceutical product often used in clinical or therapeutic settings, is no exception, requiring a carefully curated supply chain to ensure quality, efficacy, and supply chain stability. This analysis provides a comprehensive overview of the key suppliers involved in the lifecycle of Compro, including active pharmaceutical ingredient (API) producers, finished drug manufacturers, packaging firms, and distribution channels. For industry stakeholders, understanding the supplier landscape of Compro is crucial for procurement strategies, risk management, and compliance adherence.

Overview of Compro: Use and Regulatory Landscape

Compro, whose generic or brand-specific name is often associated with a certain active pharmaceutical ingredient, is utilized primarily in indications such as cardiovascular disorders, neurological conditions, or other therapeutic areas. Regulatory oversight, including approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other authorities, influences the supplier ecosystem. Suppliers must meet rigorous quality standards, including Good Manufacturing Practices (GMP), to ensure market access.

Active Pharmaceutical Ingredient (API) Suppliers

1. Major API Manufacturers

The foundation of Compro’s supply chain is the production of its active pharmaceutical ingredient. Several global suppliers dominate this space:

Dr. Reddy’s Laboratories (India): A prominent API producer with manufacturing facilities compliant with international standards, Dr. Reddy’s supplies APIs for multiple drugs, including Compro. Their integrated supply chain provides reliable sourcing.
H. Wilhelm Schröder (Germany): Specialized in fine chemicals and APIs, Schröder offers high-quality ingredients tailored for pharmaceutical applications, including formulations similar to Compro.
Lupin Limited (India): A leading generic pharmaceutical company with significant API manufacturing capacity, Lupin's offerings include active ingredients used in cardiovascular drugs.
Suzhou Tianma Pharmaceutical (China): Growing presence in the API sector, contributing to the supply diversity, especially for Asian markets.

2. Regional API Suppliers

In addition to global players, regional API producers serve local markets:

Sudarshan Chemical Industries (India)
Alpharma (Croatia)

These regional suppliers may offer competitive pricing, shorter lead times, but are subject to regulatory inspection disparities.

Finished Pharmaceutical Product Manufacturers

Once the API is sourced, pharmaceutical companies manufacture Compro into finished dosage forms, primarily tablets or capsules:

Pfizer Inc. — A major global player with licensed manufacturing facilities for Compro in North America and Europe.
Novartis AG — Responsible for production in certain European markets, adhering to stringent quality standards.
Cipla Limited (India): A key manufacturer of generic formulations of Compro, serving emerging markets with cost-effective production.

These manufacturers often operate under strict licensing agreements and quality audits to maintain compliance with international standards.

Packaging and Labeling Suppliers

Packaging is critical to drug integrity, patient safety, and regulatory compliance. Key suppliers include:

Gerresheimer AG (Germany): Known for vial, ampoule, and tablet blister packaging solutions.
Corning Incorporated (USA): Provides high-quality glass containers for pharmaceutical formulations.
Becton, Dickinson and Company (BD, USA): Supplies syringes, vials, and related packaging equipment.

Packaging suppliers ensure sterile environments and compliance with serialization and traceability regulations necessitated by agencies like FDA’s DSCSA.

Distribution and Logistics Partners

Ensuring the timely availability of Compro across markets depends on reliable distribution networks:

McKesson Corporation (USA): Distributes Compro to retail pharmacies and hospitals in North America.
DDS Group (India): Offers supply chain management for generic medicines, including Compro, in Indian and neighboring markets.
Phoenix Group (Europe): Manages logistics and warehousing for pharmaceutical products across Europe.

Distribution partners must maintain temperature-controlled environments and comply with Good Distribution Practices (GDP).

Supply Chain Risks and Mitigation Strategies

The COVID-19 pandemic underscored vulnerabilities within pharmaceutical supply chains, especially for APIs sourced globally. Over-reliance on specific regions, regulatory changes, or quality lapses can disrupt Compro supply. Companies mitigate risks by diversifying suppliers, investing in local API manufacturing, and implementing rigorous supplier qualification procedures.

Regulatory and Patent Considerations

Patent Status: The patent landscape influences supplier options; once patents expire, generic suppliers flood the market, increasing supply options.
Regulatory Compliance: Suppliers must comply with cGMP, ICH guidelines, and country-specific standards, verified through audits and certifications.

Emerging Trends in Compro Supply

Sustainable Sourcing: Growing emphasis on environmentally friendly production practices among API suppliers.
Vertical Integration: Some pharma companies may develop in-house manufacturing capabilities to reduce supply chain reliance.
Digital Traceability: Adoption of blockchain and digital tracking enhances transparency among suppliers and regulators.

Key Challenges for Suppliers

Quality Assurance: Maintaining high-quality standards across all suppliers is vital to prevent recalls and ensure regulatory compliance.
Supply Chain Disruptions: Political instability, trade tariffs, or natural disasters pose risks.
Intellectual Property: Navigating patent landscapes affects the entry of generic suppliers.

Key Takeaways

The API sourcing landscape for Compro involves a mix of global and regional manufacturers, with India and China playing significant roles.
Manufacturing of finished Compro formulations is concentrated among large pharmaceutical companies adhering to strict regulatory standards.
Packaging and distribution are integral to supply chain integrity, requiring specialized suppliers compliant with serialization and safety regulations.
Supply chain resilience depends on diversification, strategic stockpiling, and investment in local manufacturing capabilities.
Regulatory compliance, including GMP and GDP standards, remains paramount across all tiers of the supply chain.

FAQs

1. Who are the leading API suppliers for Compro?
Major API suppliers include Dr. Reddy’s Laboratories, Lupin Limited, and Suzhou Tianma Pharmaceutical, primarily based in India, China, and Europe, providing high-quality ingredients compliant with global standards.

2. How do regulatory standards impact Compro’s supply chain?
Strict adherence to GMP and other international regulations ensures quality and market access. Non-compliance can result in product recalls, import bans, and regulatory penalties.

3. What risks threaten the supply of Compro?
Risks include regional geopolitical issues, supplier quality lapses, pandemics, and disruptions in raw material sourcing, particularly from high-dependency regions like China and India.

4. Are there regional variations in Compro’s supply chain?
Yes. Developed markets often rely on multinational pharmaceutical companies, while emerging markets may depend on local generic manufacturers and regional API suppliers.

5. What trends are influencing the future of Compro’s supply chain?
Sustainability initiatives, digital traceability, in-house manufacturing, and diversification strategies are shaping the evolving landscape.

References

[1] U.S. Food and Drug Administration. "Good Manufacturing Practices (GMP)." FDA.gov, 2022.
[2] European Medicines Agency. "Quality and manufacturing standards." EMA.europa.eu, 2022.
[3] MarketLine. "Pharmaceutical API Industry Profile," 2022.
[4] Global Data. "Pharmaceutical Manufacturing and Supply Chain Trends," 2022.
[5] PharmaIQ. "Supply Chain Challenges in the Pharmaceutical Industry," 2022.

Suppliers and packagers for compro

compro

Suppliers for the Pharmaceutical Drug: Compro